Vessel co-option in cancer

[1]  P. van Dam,et al.  Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy. , 2018, Seminars in cancer biology.

[2]  V. Servois,et al.  Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastases , 2018, The journal of pathology. Clinical research.

[3]  M. Rosenblum,et al.  Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization , 2018, Nature Cell Biology.

[4]  A. Chenn,et al.  Leukaemia hijacks a neural mechanism to invade the central nervous system , 2018, Nature.

[5]  B. Bozóky,et al.  Growth patterns of colorectal cancer liver metastases and their impact on prognosis: a systematic review , 2018, BMJ open gastroenterology.

[6]  M. Oldham,et al.  A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. , 2018, Cancer cell.

[7]  P. Vermeulen,et al.  Vascularization of colorectal carcinoma liver metastasis: insight into stratification of patients for anti‐angiogenic therapies , 2018, The journal of pathology. Clinical research.

[8]  P. Wen,et al.  Phase 2 and biomarker study of trebananib, an angiopoietin‐blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma , 2018, Cancer.

[9]  A. Harris,et al.  Non-angiogenic tumours and their influence on cancer biology , 2018, Nature Reviews Cancer.

[10]  Andrea Sottoriva,et al.  Patient-derived organoids model treatment response of metastatic gastrointestinal cancers , 2018, Science.

[11]  R. Kerbel,et al.  Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa , 2018, Nature Reviews Clinical Oncology.

[12]  Catriona McLean,et al.  Inhibition of Endosteal Vascular Niche Remodeling Rescues Hematopoietic Stem Cell Loss in AML , 2018, Cell stem cell.

[13]  J. Patard,et al.  Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. , 2018, European urology.

[14]  D. McDonald,et al.  Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms. , 2018, Cancer research.

[15]  H. Wakelee,et al.  Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial , 2017, The Lancet. Oncology.

[16]  I. Durán,et al.  Systemic treatment of renal cell cancer: A comprehensive review. , 2017, Cancer treatment reviews.

[17]  R. Burger,et al.  Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses , 2017, Journal of the National Cancer Institute.

[18]  Yves Sucaet,et al.  International consensus guidelines for scoring the histopathological growth patterns of liver metastasis , 2017, British Journal of Cancer.

[19]  R. Motzer,et al.  Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  F. Winkler.  Hostile takeover: how tumours hijack pre‐existing vascular environments to thrive , 2017, The Journal of pathology.

[21]  K. Alitalo,et al.  Therapeutic targeting of the angiopoietin–TIE pathway , 2017, Nature Reviews Drug Discovery.

[22]  D. Hanahan,et al.  Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation , 2017, Science Translational Medicine.

[23]  Y. Kienast,et al.  Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade , 2017, Science Translational Medicine.

[24]  D. Dimitrov,et al.  Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. , 2017, Cancer cell.

[25]  R. Kerbel,et al.  A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature. , 2017, Cancer cell.

[26]  Michael R. Speicher,et al.  Emerging concepts in liquid biopsies , 2017, BMC Medicine.

[27]  P. Vermeulen,et al.  The histological growth patterns of colorectal cancer liver metastasis are associated with disease progression post portal vein embolization , 2017 .

[28]  James D. Brenton,et al.  Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.

[29]  Eun Sun Lee,et al.  How to Differentiate Borderline Hepatic Nodules in Hepatocarcinogenesis: Emphasis on Imaging Diagnosis , 2017, Liver Cancer.

[30]  H. Grabsch,et al.  Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial , 2017, The Lancet. Oncology.

[31]  P. Schil.  Faculty Opinions recommendation of The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. , 2017 .

[32]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[33]  W. Travis,et al.  Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer–Specific Death in Squamous Cell Carcinoma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[35]  J. Larkin,et al.  Vessel co‐option is common in human lung metastases and mediates resistance to anti‐angiogenic therapy in preclinical lung metastasis models , 2016, The Journal of pathology.

[36]  A. Schneeweiss,et al.  Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  R. Kerbel,et al.  Plasma vascular endothelial growth factor as a predictive biomarker: Door closed? , 2017, European journal of cancer.

[38]  D. Miles,et al.  Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. , 2017, European journal of cancer.

[39]  R. Kurzrock,et al.  Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non–Small Cell Lung Cancer Patients , 2016, Clinical Cancer Research.

[40]  Florence T. H. Wu,et al.  Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers. , 2016, Cancer research.

[41]  T. Mikkelsen,et al.  CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study , 2016, Oncotarget.

[42]  D. Kerr,et al.  Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. , 2016, The Lancet. Oncology.

[43]  L. Fallowfield,et al.  Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  G. G. Van den Eynden,et al.  Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases , 2016, Nature Medicine.

[45]  R. Paschke,et al.  Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses , 2016 .

[46]  Ignace Vergote,et al.  Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. , 2016, Gynecologic oncology.

[47]  Gary Box,et al.  Investigating intracranial tumour growth patterns with multiparametric MRI incorporating Gd‐DTPA and USPIO‐enhanced imaging , 2016, NMR in biomedicine.

[48]  M. Gilbert.  Antiangiogenic Therapy for Glioblastoma: Complex Biology and Complicated Results. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  K. Gatter,et al.  Evidence Showing That Tumors Can Grow Without Angiogenesis and Can Switch Between Angiogenic and Nonangiogenic Phenotypes. , 2016, Journal of the National Cancer Institute.

[50]  Gordon C Jayson,et al.  Antiangiogenic therapy in oncology: current status and future directions , 2016, The Lancet.

[51]  G. Reifenberger,et al.  EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance , 2016, Nature Communications.

[52]  Paul Bertone,et al.  EphrinB2 drives perivascular invasion and proliferation of glioblastoma stem-like cells , 2016, eLife.

[53]  S. Steinberg,et al.  Alterations in Pericyte Subpopulations Are Associated with Elevated Blood–Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer , 2016, Clinical Cancer Research.

[54]  P. Catalano,et al.  Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs mFOLFOX6 and bevacizumab (Bev) for patients (pts) with stage II/ III rectal cancer receiving pre-operative chemoradiation. , 2016 .

[55]  J. Manola,et al.  Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial , 2016, The Lancet.

[56]  J. Carles,et al.  Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients , 2016, Cell reports.

[57]  D. Hanahan,et al.  Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling , 2016, Cell reports.

[58]  G. Yousef,et al.  Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma , 2016, Journal of the National Cancer Institute.

[59]  H. Kleinman,et al.  Imaging of Angiotropism/Vascular Co-Option in a Murine Model of Brain Melanoma: Implications for Melanoma Progression along Extravascular Pathways , 2016, Scientific Reports.

[60]  R. Jain,et al.  Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages , 2016, Proceedings of the National Academy of Sciences.

[61]  W. Yung,et al.  Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas , 2016, Oncotarget.

[62]  A. Harris,et al.  Why some tumours trigger neovascularisation and others don’t: the story thus far , 2016, Chinese journal of cancer.

[63]  P. Nagy,et al.  Mechanisms of vascularization in murine models of primary and metastatic tumor growth , 2016, Chinese journal of cancer.

[64]  P. Lenzi,et al.  John Hunter and the origin of the term “angiogenesis” , 2016, Angiogenesis.

[65]  Y. Bang,et al.  Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover. , 2016 .

[66]  B. Olsen,et al.  Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair. , 2016, The Journal of clinical investigation.

[67]  S. Barry,et al.  Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer. , 2016, Cell metabolism.

[68]  K. Plate,et al.  Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma , 2015, EMBO molecular medicine.

[69]  G. Christofori,et al.  Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy , 2015, Cell reports.

[70]  E. Rofstad,et al.  Intertumor heterogeneity in vascularity and invasiveness of artificial melanoma brain metastases , 2015, Journal of Experimental & Clinical Cancer Research.

[71]  R. Kerbel,et al.  Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer , 2015, Oncotarget.

[72]  Rakesh K. Jain,et al.  Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients , 2015, Proceedings of the National Academy of Sciences.

[73]  M. Makuuchi,et al.  Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. , 2015, The Lancet. Oncology.

[74]  G. Carmeliet,et al.  The vasculature: a vessel for bone metastasis. , 2015, BoneKEy reports.

[75]  S. Paik,et al.  Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. , 2015, The Lancet. Oncology.

[76]  R. Jain,et al.  Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. , 2015, Journal of the National Cancer Institute.

[77]  J. Austin,et al.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[78]  T. Allen,et al.  The Demise of the Term Bronchioloalveolar Carcinoma. , 2015, Archives of pathology & laboratory medicine.

[79]  R. Kerbel,et al.  Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy , 2015, Clinical Cancer Research.

[80]  P. Hasleton,et al.  The percentage of lepidic growth is an independent prognostic factor in invasive adenocarcinoma of the lung , 2015, Diagnostic Pathology.

[81]  Joon-Oh Park,et al.  Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.

[82]  V. Rohde,et al.  The metastatic infiltration at the metastasis/brain parenchyma-interface is very heterogeneous and has a significant impact on survival in a prospective study , 2015, Oncotarget.

[83]  R. Kerbel,et al.  Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma. , 2015, Cancer research.

[84]  A. Warth,et al.  Prognostic Impact of Intra-alveolar Tumor Spread in Pulmonary Adenocarcinoma , 2015, The American journal of surgical pathology.

[85]  B. Olsen,et al.  Vegfa regulates perichondrial vascularity and osteoblast differentiation in bone development , 2015, Development.

[86]  J. Schlom,et al.  Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells , 2015, Cancer Immunology Research.

[87]  David R. Jones,et al.  Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[88]  E. Van Cutsem,et al.  Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. , 2015, The Lancet. Oncology.

[89]  R. Kerbel,et al.  Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib , 2015, Science Translational Medicine.

[90]  T. Tsuzuki,et al.  Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma. , 2015, American journal of clinical pathology.

[91]  I. Christensen,et al.  Growth pattern of colorectal liver metastasis as a marker of recurrence risk , 2015, Clinical & Experimental Metastasis.

[92]  Qian Zhu,et al.  Arterial blood supply of hepatocellular carcinoma is associated with efficacy of sorafenib therapy. , 2015, Annals of translational medicine.

[93]  A. Harris,et al.  Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality , 2015, EMBO molecular medicine.

[94]  David E Goertz,et al.  An overview of the influence of therapeutic ultrasound exposures on the vasculature: High intensity ultrasound and microbubble-mediated bioeffects , 2015, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[95]  J. Tímár,et al.  Mechanism of tumour vascularization in experimental lung metastases , 2015, The Journal of pathology.

[96]  Noy Pj,et al.  Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth , 2015, Oncogene.

[97]  Y. Maehara,et al.  Solitary pulmonary metastasis from malignant melanoma of the bulbar conjunctiva presenting as a pulmonary ground glass nodule: Report of a case , 2015, Thoracic cancer.

[98]  Qian Zhu,et al.  Arterial blood supply of hepatocellular carcinoma is associated with efficacy of sorafenib therapy , 2015 .

[99]  H. Schlitt,et al.  Prognosis according to histochemical analysis of liver metastases removed at liver resection , 2014, The British journal of surgery.

[100]  B. Vainer,et al.  The morphological growth patterns of colorectal liver metastases are prognostic for overall survival , 2014, Modern Pathology.

[101]  S. Ramakrishnan,et al.  Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models , 2014, Molecular Cancer Therapeutics.

[102]  P. Dayton,et al.  Vascular channels formed by subpopulations of PECAM1+ melanoma cells , 2014, Nature Communications.

[103]  S. Carmichael,et al.  Angiotropism, Pericytic Mimicry and Extravascular Migratory Metastasis in Melanoma: An Alternative to Intravascular Cancer Dissemination , 2014, Cancer Microenvironment.

[104]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[105]  Andreas Sashegyi,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.

[106]  R. Paschke,et al.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial , 2014, The Lancet.

[107]  S. Martinez,et al.  Glioblastoma: A Pathogenic Crosstalk between Tumor Cells and Pericytes , 2014, PloS one.

[108]  T. Mikkelsen,et al.  Mechanisms of Glioma Formation: Iterative Perivascular Glioma Growth and Invasion Leads to Tumor Progression, VEGF-Independent Vascularization, and Resistance to Antiangiogenic Therapy12 , 2014, Neoplasia.

[109]  Harald Sontheimer,et al.  Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells , 2014, Nature Communications.

[110]  W. Gradishar,et al.  Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. , 2014 .

[111]  M. Gore,et al.  Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. , 2014, The Lancet. Oncology.

[112]  C. Grommes,et al.  Bevacizumab for the treatment of high-grade glioma: an update after Phase III trials , 2014, Expert opinion on biological therapy.

[113]  Ximing J. Yang,et al.  Glomerular sparing pattern in primary kidney neoplasms: clinical, morphological and immunohistochemical study. , 2014, American journal of clinical and experimental urology.

[114]  J. Llovet,et al.  Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design , 2014, Clinical Cancer Research.

[115]  M. Kris,et al.  Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis , 2014, Cell.

[116]  D. Schadendorf,et al.  Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma , 2014, Nature.

[117]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[118]  Michael W Sill,et al.  Improved survival with bevacizumab in advanced cervical cancer. , 2014, The New England journal of medicine.

[119]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[120]  Rolf Kaiser,et al.  Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. , 2014, The Lancet. Oncology.

[121]  A. Reynolds,et al.  Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions , 2014, Angiogenesis.

[122]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[123]  Michael Simons,et al.  Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis , 2013, Nature.

[124]  M. Aghi,et al.  β1 integrin: Critical path to antiangiogenic therapy resistance and beyond. , 2014, Cancer research.

[125]  M. Buyse,et al.  Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer , 2013 .

[126]  Frank Winkler,et al.  Invasion patterns in brain metastases of solid cancers. , 2013, Neuro-oncology.

[127]  Y. Kienast,et al.  Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy , 2013, Clinical Cancer Research.

[128]  A. Marx,et al.  Endothelial transdifferentiation in hepatocellular carcinoma: loss of Stabilin‐2 expression in peri‐tumourous liver correlates with increased survival , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[129]  T. Tsuzuki,et al.  Growth pattern, an important pathologic prognostic parameter for clear cell renal cell carcinoma. , 2013, American journal of clinical pathology.

[130]  L. Jeng,et al.  Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  R. Swann,et al.  Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy , 2013, Clinical Cancer Research.

[132]  Demin Li,et al.  A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis , 2013, Cancer cell.

[133]  P. Fasching,et al.  Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  I. Mackenzie,et al.  Angiotropism in Primary Cutaneous Melanoma With Brain Metastasis: A Study of 20 Cases , 2013, The American Journal of dermatopathology.

[135]  P. Philip,et al.  Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. , 2013, European journal of cancer.

[136]  A. Harris,et al.  Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? , 2013, Cancer medicine.

[137]  N. Petrelli,et al.  Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. , 2013, Journal of the National Cancer Institute.

[138]  Thierry Gil,et al.  Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. , 2013, The Lancet. Oncology.

[139]  Mina J. Bissell,et al.  The perivascular niche regulates breast tumor dormancy , 2013, Nature Cell Biology.

[140]  Catherine C. Park,et al.  β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. , 2013, Cancer research.

[141]  R. Jain.  Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  C. Qian.  Hijacking the vasculature in ccRCC—co-option, remodelling and angiogenesis , 2013, Nature Reviews Urology.

[143]  R. Kerbel,et al.  A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. , 2013, Cancer research.

[144]  R. Greil,et al.  AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  Lauren McCann,et al.  A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. , 2013, European journal of cancer.

[146]  R. McLendon,et al.  Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth , 2013, Cell.

[147]  J. A. van der Laak,et al.  Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2 , 2013, PloS one.

[148]  L. Ellis,et al.  Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. , 2013, Cancer cell.

[149]  Frederik Nevens,et al.  Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. , 2013, Cancer letters.

[150]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[151]  N. Petrelli,et al.  Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[152]  K. Flaherty,et al.  Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[153]  E. Tartour,et al.  VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. , 2013, Cancer research.

[154]  J. Hecht,et al.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. , 2012, The Lancet. Oncology.

[155]  D. Reisman,et al.  Rapid liver enlargement and hepatic failure secondary to radiographic occult tumor invasion: two case reports and review of the literature , 2012, Journal of Medical Case Reports.

[156]  J. Wilmott,et al.  Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma , 2012, Histopathology.

[157]  Daniela Prayer,et al.  Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases , 2012, Clinical & Experimental Metastasis.

[158]  Swe Swe Myint,et al.  Changes in specialized blood vessels in lymph nodes and their role in cancer metastasis , 2012, Journal of Translational Medicine.

[159]  Csaba Bödör,et al.  Structural analysis of oval‐cell–mediated liver regeneration in rats , 2012, Hepatology.

[160]  D. Zagzag,et al.  Mechanisms of glioma-associated neovascularization. , 2012, The American journal of pathology.

[161]  P. Moss,et al.  Recruitment mechanisms of primary and malignant B cells to the human liver , 2012, Hepatology.

[162]  G. Scagliotti,et al.  Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[163]  E. Van Cutsem,et al.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  D. Cheresh,et al.  VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. , 2012, Cancer cell.

[165]  C. Lebbé,et al.  Sorafenib in advanced melanoma: a critical role for pharmacokinetics? , 2012, British Journal of Cancer.

[166]  J. Frank,et al.  Phase contrast MRI is an early marker of micrometastatic breast cancer development in the rat brain , 2012, NMR in biomedicine.

[167]  P. Kantoff,et al.  Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[168]  G. G. Van den Eynden,et al.  The histological growth pattern of colorectal cancer liver metastases has prognostic value , 2012, Clinical & Experimental Metastasis.

[169]  J. Gronych,et al.  Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. , 2012, Cancer research.

[170]  J. Scoazec,et al.  Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines , 2012, Oncogene.

[171]  Jiri Bartek,et al.  Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth , 2012, The Journal of experimental medicine.

[172]  Barbara Sennino,et al.  Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. , 2012, Cancer discovery.

[173]  P. Lemotte,et al.  TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. , 2012, Cancer cell.

[174]  R. Greil,et al.  First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[175]  Zainab N. Khan,et al.  Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. , 2012, Cancer cell.

[176]  O. Mir,et al.  Sorafenib exposure decreases over time in patients with hepatocellular carcinoma , 2012, Investigational New Drugs.

[177]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[178]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[179]  E. Perez,et al.  RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[180]  B. Döme,et al.  Lack of Angiogenesis in Experimental Brain Metastases , 2011, Journal of neuropathology and experimental neurology.

[181]  R. Kerbel.  Reappraising antiangiogenic therapy for breast cancer. , 2011, Breast.

[182]  G. Coukos,et al.  The parallel lives of angiogenesis and immunosuppression: cancer and other tales , 2011, Nature Reviews Immunology.

[183]  A. Harris,et al.  DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. , 2011, Cancer research.

[184]  Yuquan Wei,et al.  Distinct contributions of angiogenesis and vascular co-option during the initiation of primary microtumors and micrometastases. , 2011, Carcinogenesis.

[185]  H. Atkins,et al.  Targeting tumor vasculature with an oncolytic virus. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[186]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[187]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[188]  N. Robert,et al.  Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. , 2011, Clinical breast cancer.

[189]  H. Sontheimer,et al.  Bradykinin Promotes the Chemotactic Invasion of Primary Brain Tumors , 2011, The Journal of Neuroscience.

[190]  D. Berney,et al.  Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib , 2011, Oncogene.

[191]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[192]  R. Kerbel,et al.  Antiangiogenic therapy: impact on invasion, disease progression, and metastasis , 2011, Nature Reviews Clinical Oncology.

[193]  T. Taxt,et al.  Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma , 2011, Proceedings of the National Academy of Sciences.

[194]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[195]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[196]  M. Weller,et al.  Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence , 2011, Current neurology and neuroscience reports.

[197]  N. Petrelli,et al.  Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[198]  Tracy T Batchelor,et al.  Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. , 2011, Cancer research.

[199]  J. Christensen,et al.  HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. , 2010, Cancer research.

[200]  A. Palestine,et al.  Vascular co-option in lung cancer metastatic to the eye after treatment with bevacizumab , 2010, Journal of ophthalmic inflammation and infection.

[201]  Luke A. Gilbert,et al.  DNA Damage-Mediated Induction of a Chemoresistant Niche , 2010, Cell.

[202]  Zev Rosenwaks,et al.  Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration , 2010, Nature.

[203]  D. Nam,et al.  Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. , 2010, Cancer cell.

[204]  R. Schilsky,et al.  Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[205]  S. Rosenberg,et al.  Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. , 2010, Cancer research.

[206]  Arlene Chan,et al.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[207]  Kinuyo Hatanaka,et al.  Depiction of Portal Supply in Early Hepatocellular Carcinoma and Dysplastic Nodule: Value of Pure Arterial Ultrasound Imaging in Hepatocellular Carcinoma , 2010, Oncology.

[208]  I. Kasman,et al.  Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy , 2010, Clinical Cancer Research.

[209]  H. Iwata,et al.  Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer , 2010, Breast Cancer Research and Treatment.

[210]  D. Schadendorf,et al.  Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma , 2010, The Journal of experimental medicine.

[211]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[212]  R. Ramlau,et al.  Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[213]  P. A. Futreal,et al.  Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. , 2010, Cancer research.

[214]  G. Fuller,et al.  Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice , 2010, Neuro-oncology.

[215]  R. Kerbel,et al.  Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer , 2009, Molecular Cancer Therapeutics.

[216]  Jochen Herms,et al.  Real-time imaging reveals the single steps of brain metastasis formation , 2010, Nature Medicine.

[217]  D. Damek,et al.  The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis , 2010, Journal of Neuro-Oncology.

[218]  D. Briscoe,et al.  Cutting Edge: Vascular Endothelial Growth Factor-Mediated Signaling in Human CD45RO+ CD4+ T Cells Promotes Akt and ERK Activation and Costimulates IFN-γ Production , 2009, The Journal of Immunology.

[219]  Jochen Herms,et al.  Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and peritumoral angiogenesis , 2009, Glia.

[220]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[221]  J. D. de Groot,et al.  Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy , 2009, Clinical Cancer Research.

[222]  Apurva A Desai,et al.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[223]  N. Sibson,et al.  The Vascular Basement Membrane as “Soil” in Brain Metastasis , 2009, PloS one.

[224]  S. Yousem.  Peripheral squamous cell carcinoma of lung: patterns of growth with particular focus on airspace filling. , 2009, Human pathology.

[225]  Sara Rockwell,et al.  Hypoxia and radiation therapy: past history, ongoing research, and future promise. , 2009, Current molecular medicine.

[226]  R. Jain,et al.  VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer , 2009, Nature Reviews Clinical Oncology.

[227]  R. Ramlau,et al.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[228]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[229]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[230]  Michiie Sakamoto,et al.  Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia , 2009, Hepatology.

[231]  I. Kasman,et al.  PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. , 2009, Cancer cell.

[232]  Jung‐Sik Kim,et al.  Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells. , 2009, Cellular immunology.

[233]  L. Stalpers,et al.  Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme , 2009, BMC Cancer.

[234]  R. Scolyer,et al.  Angiotropism is an Independent Predictor of Local Recurrence and In-transit Metastasis in Primary Cutaneous Melanoma , 2008, The American journal of surgical pathology.

[235]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[236]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[237]  L. Terracciano,et al.  Patterns of liver infiltration in lymphoproliferative disease , 2008, Histopathology.

[238]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[239]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[240]  P. Wen,et al.  Bevacizumab for recurrent malignant gliomas , 2008, Neurology.

[241]  D. Ribatti.  Judah Folkman, a pioneer in the study of angiogenesis , 2008, Angiogenesis.

[242]  E. van Marck,et al.  Different growth patterns of non-small cell lung cancer represent distinct biologic subtypes. , 2008, The Annals of thoracic surgery.

[243]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[244]  Satoshi Tanaka,et al.  Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region , 2007, Nature Biotechnology.

[245]  Pieter Wesseling,et al.  Diffuse glioma growth: a guerilla war , 2007, Acta Neuropathologica.

[246]  P. V. Van Schil,et al.  Distinct angiogenic and non‐angiogenic growth patterns of lung metastases from renal cell carcinoma , 2007, Histopathology.

[247]  O. Matsui,et al.  A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: ‘bile ductular carcinoma’ , 2007, Histopathology.

[248]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[249]  A. Gregory Sorensen,et al.  Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.

[250]  D. Carbone,et al.  Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. , 2007, Blood.

[251]  R. Johnson,et al.  Hypoxia: A key regulator of angiogenesis in cancer , 2007, Cancer and Metastasis Reviews.

[252]  D. Hicklin,et al.  Simultaneous blockade of VEGFR‐1 and VEGFR‐2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation , 2007, International journal of cancer.

[253]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[254]  H. Stein,et al.  Frequency and diagnostic patterns of lymphomas in liver biopsies with respect to the WHO classification , 2007, Virchows Archiv.

[255]  B. Teh,et al.  Prospects for Vasculature Reorganization in Sentinel Lymph Nodes , 2007, Cell cycle.

[256]  O. Feron,et al.  Effects of Vascular Endothelial Growth Factor on the Lymphocyte-Endothelium Interactions: Identification of Caveolin-1 and Nitric Oxide as Control Points of Endothelial Cell Anergy1 , 2007, The Journal of Immunology.

[257]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[258]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[259]  T. Tsuji,et al.  Observation of microvascular casts of human hepatocellular carcinoma by scanning electron microscopy , 1991, Gastroenterologia Japonica.

[260]  M. Hendrix,et al.  Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. , 2007, The American journal of pathology.

[261]  N. Reinmuth,et al.  Prognostic significance of vessel architecture and vascular stability in non-small cell lung cancer. , 2007, Lung cancer.

[262]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[263]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[264]  K. Jooss,et al.  Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF–Secreting Cancer Immunotherapy , 2006, Clinical Cancer Research.

[265]  I. Jonassen,et al.  Angiogenesis-independent tumor growth mediated by stem-like cancer cells , 2006, Proceedings of the National Academy of Sciences.

[266]  D. Hicklin,et al.  Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors , 2006, Science.

[267]  K. Gatter,et al.  Is nonangiogenesis a novel pathway for cancer progression? A study using 3-dimensional tumour reconstructions , 2006, British Journal of Cancer.

[268]  D. Fishman,et al.  Vascular endothelial growth factor–regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases , 2006, International journal of cancer.

[269]  M. Oertel,et al.  Cell competition leads to a high level of normal liver reconstitution by transplanted fetal liver stem/progenitor cells. , 2006, Gastroenterology.

[270]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[271]  J. Tímár,et al.  Lymphangiogenesis Correlates with Lymph Node Metastasis, Prognosis, and Angiogenic Phenotype in Human Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[272]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[273]  J. A. van der Laak,et al.  Gliomatosis cerebri: quantitative proof of vessel recruitment by cooptation instead of angiogenesis. , 2005, Journal of neurosurgery.

[274]  A. Nicholson,et al.  Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer , 2005, Oncogene.

[275]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[276]  Dr. Johannes Erichsen.  Zwei Fälle von Carcinosis acuta miliaris , 1861, Archiv für pathologische Anatomie und Physiologie und für klinische Medicin.

[277]  K. Allison,et al.  Radiographically occult, diffuse intrasinusoidal hepatic metastases from primary breast carcinomas: a clinicopathologic study of 3 autopsy cases. , 2004, Archives of pathology & laboratory medicine.

[278]  C. Lugassy,et al.  Angiotropic malignant melanoma and extravascular migratory metastasis: description of 36 cases with emphasis on a new mechanism of tumour spread , 2004, Pathology.

[279]  Pieter Wesseling,et al.  Antiangiogenic Therapy of Cerebral Melanoma Metastases Results in Sustained Tumor Progression via Vessel Co-Option , 2004, Clinical Cancer Research.

[280]  M. Kojiro.  ‘Nodule-in-Nodule’ Appearance in Hepatocellular Carcinoma: Its Significance as a Morphologic Marker of Dedifferentiation , 2004, Intervirology.

[281]  J. Weyler,et al.  Prognostic value of nonangiogenic and angiogenic growth patterns in non-small-cell lung cancer , 2004, British Journal of Cancer.

[282]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[283]  E. Ruoslahti,et al.  Vascular zip codes in angiogenesis and metastasis. , 2004, Biochemical Society transactions.

[284]  L. Claesson‐Welsh,et al.  The Adaptor Protein Shb Binds to Tyrosine 1175 in Vascular Endothelial Growth Factor (VEGF) Receptor-2 and Regulates VEGF-dependent Cellular Migration* , 2004, Journal of Biological Chemistry.

[285]  E. van Marck,et al.  Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia , 2004, British Journal of Cancer.

[286]  C. Degott,et al.  Angiogenesis and extracellular matrix remodelling in bronchioloalveolar carcinomas: distinctive patterns in mucinous and non‐mucinous tumours , 2004, Histopathology.

[287]  A. Miodoński,et al.  Angiomorphology of the human renal clear cell carcinoma , 1989, Virchows Archiv A.

[288]  M. Aoyagi,et al.  Invasion of experimental rat brain tumor: early morphological changes following microinjection of C6 glioma cells , 2004, Acta Neuropathologica.

[289]  H. Fujii,et al.  Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines , 2004, Cancer Immunology, Immunotherapy.

[290]  N. Pryer,et al.  Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. , 2003, Molecular cancer therapeutics.

[291]  A. Heerschap,et al.  Vascular endothelial growth factor‐A determines detectability of experimental melanoma brain metastasis in GD‐DTPA‐enhanced MRI. , 2003, International journal of cancer.

[292]  D. Carbone,et al.  VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. , 2003, Blood.

[293]  C. Colpaert,et al.  Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition , 2003, Histopathology.

[294]  B. Döme,et al.  A Novel Concept of Glomeruloid Body Formation in Experimental Cerebral Metastases , 2003, Journal of neuropathology and experimental neurology.

[295]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[296]  Kenneth J. Hillan,et al.  Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1 , 2003, Science.

[297]  R. Bachelder,et al.  Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. , 2002, Cancer research.

[298]  H. Kleinman,et al.  Pericytic-Like Angiotropism of Glioma and Melanoma Cells , 2002, The American Journal of dermatopathology.

[299]  C. Lugassy,et al.  Angiotropism in cutaneous melanoma: a prognostic factor strongly predicting risk for metastasis. , 2002, The Journal of investigative dermatology.

[300]  Eugene S. Kim,et al.  Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[301]  B. Döme,et al.  Vascularization of cutaneous melanoma involves vessel co‐option and has clinical significance , 2002, The Journal of pathology.

[302]  N. Ferrara,et al.  VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism , 2002, Nature.

[303]  D. Hanahan,et al.  VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. , 2002, Cancer cell.

[304]  D. Hicklin,et al.  Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.

[305]  A. Nicholson,et al.  Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas , 2002, British Journal of Cancer.

[306]  P. Wesseling,et al.  Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. , 2002, Cancer research.

[307]  E. van Marck,et al.  Lack of angiogenesis in lymph node metastases of carcinomas is growth pattern‐dependent , 2002, Histopathology.

[308]  W. Leenders,et al.  Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. , 2002, Endothelium : journal of endothelial cell research.

[309]  R. Jain,et al.  LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. , 2001, Cancer research.

[310]  E. van Marck,et al.  Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia , 2001, The Journal of pathology.

[311]  P. Brenchley,et al.  Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas , 2001, Histopathology.

[312]  D. Hinton,et al.  Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. , 2001, Blood.

[313]  K. Kinzler,et al.  Cell surface tumor endothelial markers are conserved in mice and humans. , 2001, Cancer research.

[314]  M. Westphal,et al.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.

[315]  A. Carretta,et al.  Evaluation of radiological and pathological prognostic factors in surgically-treated patients with bronchoalveolar carcinoma. , 2001, European Journal of Cardio-Thoracic Surgery.

[316]  N. Rahimi,et al.  Identification of Tyrosine Residues in Vascular Endothelial Growth Factor Receptor-2/FLK-1 Involved in Activation of Phosphatidylinositol 3-Kinase and Cell Proliferation* , 2001, The Journal of Biological Chemistry.

[317]  K. Naresh,et al.  Angiogenesis is redundant for tumour growth in lymph node metastases , 2001, Histopathology.

[318]  S. Hamilton-Dutoit,et al.  Patterns of angiogenesis in nonsmall‐cell lung carcinoma , 2001, Cancer.

[319]  P. Carmeliet,et al.  Heterogeneous vascular dependence of tumor cell populations. , 2001, The American journal of pathology.

[320]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[321]  S. Wexner,et al.  Angiogenesis of liver metastases , 2000, Diseases of the colon and rectum.

[322]  M. Westphal,et al.  Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. , 2000, Neoplasia.

[323]  R. Price,et al.  Evidence for novel non-angiogenic pathway in breast-cancer metastasis , 2000, The Lancet.

[324]  Peter Bohlen,et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity , 2000 .

[325]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[326]  R. Semelka,et al.  Perilesional enhancement of hepatic metastases: correlation between MR imaging and histopathologic findings-initial observations. , 2000, Radiology.

[327]  S. Kido,et al.  Prognostic value of bronchiolo-alveolar carcinoma component of small lung adenocarcinoma. , 1999, The Annals of thoracic surgery.

[328]  D. Hicklin,et al.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.

[329]  P. Meltzer,et al.  Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. , 1999, The American journal of pathology.

[330]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[331]  Y. Fujio,et al.  Akt Mediates Cytoprotection of Endothelial Cells by Vascular Endothelial Growth Factor in an Anchorage-dependent Manner* , 1999, The Journal of Biological Chemistry.

[332]  G. Dickersin,et al.  Ultrastructural and immunohistochemical studies of the periendothelial matrix in human melanoma: evidence for an amorphous matrix containing laminin , 1999, Journal of cutaneous pathology.

[333]  M. Kojiro,et al.  Vascularization of small hepatocellular carcinomas: correlation with differentiation. , 1999, Liver.

[334]  D. Carbone,et al.  Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.

[335]  M. Kojiro,et al.  Expression of vascular endothelial growth factor in human hepatocellular carcinoma , 1998, Hepatology.

[336]  D. Witte,et al.  Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice , 1997 .

[337]  M Buyse,et al.  Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. , 1997, The American journal of pathology.

[338]  A. Kaider,et al.  Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithelial neoplasia. , 1997, Journal of the National Cancer Institute.

[339]  M. Buyse,et al.  Immunocytochemical markers in stage I lung cancer: relevance to prognosis. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[340]  A. Nicholson,et al.  Angiogenesis in primary lung cancer and lung secondaries. , 1996, European journal of cancer.

[341]  T. Terada,et al.  A morphometric and immunohistochemical study on angiogenesis of human metastatic carcinomas of the liver , 1996, Hepatology.

[342]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[343]  G. Groenewegen,et al.  Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. , 1996, Blood.

[344]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[345]  S. Arii,et al.  Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor , 1996, Hepatology.

[346]  T. Terada,et al.  Histologic growth patterns of metastatic carcinomas of the liver. , 1996, Japanese journal of clinical oncology.

[347]  R. Jain,et al.  During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. , 1996, Nature medicine.

[348]  L. Ellis,et al.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. , 1995, Cancer research.

[349]  M. Toi,et al.  Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[350]  M. Kage,et al.  Pathomorphologic characteristics of small hepatocellular carcinoma: A special reference to small hepatocellular carcinoma with indistinct margins , 1995, Hepatology.

[351]  Setsuo Hirohashi,et al.  Small adenocarcinoma of the lung. Histologic characteristics and prognosis , 1995 .

[352]  D J Ruiter,et al.  Quantitative immunohistological analysis of the microvasculature in untreated human glioblastoma multiforme. Computer-assisted image analysis of whole-tumor sections. , 1994, Journal of neurosurgery.

[353]  A. Krüger,et al.  Pattern and load of spontaneous liver metastasis dependent on host immune status studied with a lacZ transduced lymphoma , 1994 .

[354]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[355]  K. Tanikawa,et al.  Sinusoidal capillarization in small hepatocellular carcinoma , 1994, Pathology international.

[356]  R. Kerbel,et al.  Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. , 1994, The American journal of pathology.

[357]  K. Lapis,et al.  Morphological aspects of angiogenesis in experimental liver metastases. , 1993, The American journal of pathology.

[358]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[359]  F. Callea,et al.  Pathology of hepatocellular carcinoma , 1993, Journal of surgical oncology. Supplement.

[360]  C. Angeletti,et al.  Relation of neovascularisation to metastasis of non-small-cell lung cancer , 1992, The Lancet.

[361]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[362]  J. Risteli,et al.  Immunohistochemical Evidence that Lung Carcinomas Grow on Alveolar Basement Membranes , 1990, The American journal of surgical pathology.

[363]  N. Ferrara,et al.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.

[364]  A. Kolin,et al.  Role of arterial occlusion in pulmonary scar cancers. , 1988, Human Pathology.

[365]  Noriyuki Moriyama,et al.  Pathology of small hepatocellular carcinoma. A proposal for a new gross classification , 1987, Cancer.

[366]  M. Kojiro,et al.  ULTRASTRUCTURAL STUDY OF HEPATOCELLULAR CARCINOMA WITH REPLACING GROWTH PATTERN , 1985, Acta pathologica japonica.

[367]  O. Matsui,et al.  Dynamic Computed Tomography During Arterial Portography: The Most Sensitive Examination for Small Hepatocellular Carcinomas , 1985, Journal of computer assisted tomography.

[368]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[369]  M. Kojiro,et al.  Histologic growth pattern of hepatocellular carcinoma: relationship to orcein (hepatitis B surface antigen)-positive cells in cancer tissue. , 1982, Human pathology.

[370]  D. Lytton,et al.  Galen on abnormal swellings. , 1978, Journal of the history of medicine and allied sciences.

[371]  I. Fidler.  Biological behavior of malignant melanoma cells correlated to their survival in vivo. , 1975, Cancer research.

[372]  H. Attwood.  The Spread of Tumours in the Human Body , 1974 .

[373]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[374]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[375]  M. Greenblatt,et al.  Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. , 1968, Journal of the National Cancer Institute.

[376]  A. Margulis,et al.  Histologic type‐specific vascular patterns in rat tumors , 1967, Cancer.

[377]  M. B. Rosenblatt,et al.  Primary and metastatic bronciolo-alveolar carcinoma. , 1967, Diseases of the chest.

[378]  F. Bierring,et al.  CELLULAR CHANGES IN THE VICINITY OF METASTATIC CARCINOMA, OBSERVED BY LIGHT AND ELECTRON MICROSCOPY. , 1964, Oncologia.

[379]  A. J. Watson.  Diffuse intra-sinusoidal metastatic carcinoma of the liver. , 1955, The Journal of pathology and bacteriology.

[380]  C. Breedis,et al.  The blood supply of neoplasms in the liver. , 1954, The American journal of pathology.

[381]  A. Lindgren.  The vascular supply of tumours with special reference to the capillary angioarchitekture. , 2009, Acta pathologica et microbiologica Scandinavica.

[382]  K. Ikeda.  Alveolar Cell Carcinoma of the Lung , 1945 .

[383]  H. Greene.  HETEROLOGOUS TRANSPLANTATION OF MAMMALIAN TUMORS I. THE TRANSFER OF RABBIT TUMORS TO ALIEN SPECIES , 1941 .

[384]  H. Scherer.  Structural Development in Gliomas , 1938 .

[385]  James Ewing,et al.  Neoplastic Diseases: A Treatise on Tumours , 1928, The Indian Medical Gazette.

[386]  F. Helvestine.  Primary Carcinoma of the Liver , 1922 .

[387]  E. Goldmann.  The Growth of Malignant Disease in Man and the Lower Animals, with special reference to the Vascular System. , 1907, Proceedings of the Royal Society of Medicine.